Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04397718 · ClinicalTrials.gov registry record · Phase 2
Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT04397718: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT04397718 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04397718, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
Interventions
- OTHER Saline
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04397718
The ClinicalTrials.gov registry entry for NCT04397718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04397718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04397718 about?
NCT04397718 is a clinical study titled "Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization". The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.
What is the current status of trial NCT04397718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2020-07-06. Estimated completion is 2021-06-08.
What interventions are being tested in trial NCT04397718?
The interventions under investigation include: Saline (OTHER), Degarelix (DRUG).
Who is sponsoring clinical trial NCT04397718?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.